Taft attorney Stephen Auten will present at the American Conference Institute’s Summit on U.S. Biosimilars on April 21 in Munich, Germany. Auten’s presentation is titled “Biosimilars Litigation Spotlight: Immediate Action Plans for Innovators and Biosimilars to Prepare For the Battles to Come.”
Auten is head of Taft's Pharmaceutical and Life Sciences Litigation practice area. He is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators and others on his LinkedIn blog "Hatch Waxman ANDA Litigation Forum," which has more than 5,500 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation and biosimilar market opportunities.